<DOC>
	<DOCNO>NCT01727869</DOCNO>
	<brief_summary>This open-label , multicenter , ascend multiple dose study REGN1400 alone combination erlotinib cetuximab administer patient certain type cancer .</brief_summary>
	<brief_title>Study REGN1400 Alone Combination With Erlotinib Cetuximab Patients With Certain Types Cancer</brief_title>
	<detailed_description />
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria include , limited , follow : 1 . Confirmed diagnosis certain unresectable metastatic cancer 2 . Adequate Eastern Cooperative Oncology Group ( ECOG ) performance status 3 . Adequate hepatic , renal bone marrow function 4 . Resolution toxicity prior therapy grade less than/ = 1 Exclusion Criteria include , limited , follow : 1 . Active brain metastasis 2 . Thromboembolic event &lt; 6 month prior study 3 . Patients recent history ( within 5 year ) another malignancy . 4 . Investigational antitumor treatment maximum 4 halflives administer 30 day prior initial administration REGN1400 5 . Patients pregnant nursing 6 . Prior treatment ErbB3 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>